Women of worth (WOW) project

Submission date 17/02/2020	Recruitment status No longer recruiting	 Prospectiv Protocol
Registration date 20/04/2020	Overall study status Completed	[_] Statistical [X] Results
Last Edited 18/01/2023	Condition category Other	[_] Individual

vely registered

- l analysis plan
- participant data

Plain English summary of protocol

Background and study aims

The African continent is currently undergoing a youth bulge. It is estimated that by 2030, 1 in every 4 individuals will be African, the vast majority of them under the age of 35 years. However, over 40% of all new HIV infections occur among youth and 85% of young people living with HIV live in Sub-Saharan Africa. Adolescents and young adults are at increased risk of HIV infection due to the many developmental, psychological, social, and structural transitions that take place in this period of the life course, yet engaging and retaining adolescents actively in health care promotion and provision is challenging in every setting worldwide.

Adolescent girls and young women (AGYW) are particularly affected and bear the brunt of the African HIV epidemic. In South Africa, young women are 4-6 fold more likely to be HIV infected than their male counterparts and in 2014 South African girls alone contributed 10% to global new HIV infections among 15-19-year-old girls. The HIV epidemic in South Africa is generalised and dominated by heterosexual HIV transmission. Drivers of HIV risk among young South African women include early age of sexual debut (<15 yrs), multiple and often older sexual partners, inconsistent/ poor condom use (<50%), coercion and violence (10%), trans-generational sex (25%), transactional sex (25%), and sex with strangers (12%). This correlates with the high prevalence of HIV and other STI's, as well as the high incidence of teenage pregnancy (94 000 SA school girls fell pregnant in 2011) in South African young women and girls.

The WOW study aim is to enhance participants' sexual and reproductive health and well-being through preventive and promotive health and psychosocial interventions, whilst enhancing their meaningful transition to adulthood.

Who can participate?

Both HIV-infected and un-infected young women aged 19-24 years

What does the study involve?

The first 5,000 participants will be randomised to receive either a care "empowerment" initiative alone, or to an empowerment programme attached to R300 cash incentive conditional on attendance. The next 5,000 participants will all receive care plus cash incentive based on the success of the initiative in the first 5,000 participants. Each participant will receive up to 12 months' active empowerment intervention and up to 36 months' passive clinic service, including uptake monitoring and evaluation.

What are the possible benefits and risks of participating? Possible benefits include:

1. A reduction in the measured outcomes, including HIV incidence and unintended pregnancy prevalence in young women

The incentive + care package will encourage more women to attend the empowerment sessions and directly or indirectly lead to an improvement in measurement outcomes, greater than that seen with the care alone package (as has been in seen in similar intervention studies)
 This project will supplement a broader Global Fund project run by the DTHF under the auspices of the Western Cape Provincial Government and will support achievement of the project's overall goals.

This project does not pose any threat to participant physical or emotional wellbeing; but it is possible that they could suffer loss of privacy or be stigmatized in some way due to participation

Where is the study run from? Desmond Tutu HIV Foundation (South Africa)

When is the study starting and how long is it expected to run for? May 2017 to December 2020

Who is funding the study?

1. The Global Fund for AIDS, Tuberculosis, and Malaria

2. Health Department, Provincial government of the Western Cape (PAWC) (South Africa)

Who is the main contact? Harley Edwards Harley.edwards@hiv-research.org.za Prof. Linda-Gail Becker Linda-Gail.Bekker@hiv-research.org.za Tamlyn Buhler Tammy.Buhler@hiv-research.org.za

Contact information

Type(s) Scientific

Contact name Prof Linda-Gail Bekker

ORCID ID http://orcid.org/0000-0002-0755-4386

Contact details

DESMOND TUTU HIV FOUNDATION Professor Linda-Gail Bekker Chief Operating Officer, DTHF; Deputy Director, DTHC Faculty of Health Sciences University of Cape Town Anzio Road, Observatory Cape Town South Africa 7705 +27 (0)21 4066959 Linda-Gail.Bekker@hiv-research.org.za

Type(s)

Public

Contact name Mrs Tamlyn Buhler

Contact details

DESMOND TUTU HIV FOUNDATION Snr Executive Professional Assistant Professor Linda-Gail Bekker Chief Operating Officer, DTHF; Deputy Director, DTHC Faculty of Health Sciences University of Cape Town Anzio Road, Observatory Cape Town South Africa 7705 +27 (0)21 4066959 Tammy.Buhler@hiv-research.org.za

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers WOW Protocol

Study information

Scientific Title A social protection plus empowerment programme for young women (19-24 years)

WOW

Study objectives

 Both incentive + care and care only packages will result in a reduction in the measured outcomes, including HIV incidence and unintended pregnancy prevalence in young women
 The incentive + care package will encourage more women to attend the empowerment sessions and directly or indirectly lead to an improvement in measurement outcomes, greater than that seen with the care alone package (as has been in seen in similar intervention studies) 3. This project will supplement a broader Global Fund project run by the DTHF under the auspices of the Western Cape Provincial Government and will support the achievement of the project's overall goals

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 04/04/2017, University of Cape Town Faculty of Health Sciences Human Research Ethics Committee (Room E53-46 Old Main Building, Groote Schuur Hospital, Observatory, 7925, Cape Town, South Africa; +27 (0) 21 406 6492; sumayah.ariefdien@uct.ac.za), ref: 033/2017

Study design

Interventional randomized controlled trial with follow up non-randomised study

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s)

Community

Study type(s) Quality of life

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

None

Interventions

The first 5,000 participants enrolled will be randomly assigned to either a care "empowerment" initiative alone, or to an empowerment programme attached to R300 cash incentive conditional on attendance.

The next 5,000 participants will all receive care plus cash incentive (this group of participants has been added after the initial recruitment started)

Each participant will receive up to 12 months' active empowerment intervention and up to 36 months' passive clinic service, including uptake monitoring and evaluation.

After registration into the biometric data capturing system and being assigned a unique participant identification number (PID) also referred to as a 'client code', participants officially enrol once they complete attendance of the first empowerment session by checking in and then out using fingerprints captured in said system.

The PIDs are then randomised into one of the two study arms by the following randomization process:

- A list of non-randomized participants that have attended the session is extracted
- A randomization seed is generated from a concatenation of PIDs
- This seed is uploaded to a randomization service (https://random.org) for randomization
- A list of participants for each study arm is generated and then saved to a randomization table
- together with the randomization seed and the date of randomization
- The randomisation is documented in a Payment Randomisation Note (PRN)

Intervention Type

Behavioural

Primary outcome measure

At baseline, programme exit and at follow up intervals from 12 months after enrolment: HIV incidence measured using self-report questionnaires and participant health records as and where available from Western Cape Department of Health records.

Secondary outcome measures

At baseline, programme exit and at follow up intervals from 12 months after enrolment, selfreport responses will be cross referenced with participant health records as and where available from Western Cape Department of Health (WCDOH) records.

- 1. Pregnancy prevalence measured using self-report questionnaires and WCDOH health records.
- 2. Unwanted pregnancies measured using self-report questionnaires.
- 3. Terminations measured using self-report questionnaires
- 4. STIs measured using self-report questionnaires and WCDOH health records
- 5. Contraception adherence measured using self-report questionnaires and WCDOH health records
- 6. ANC attendance measured using self-report questionnaires
- 7. HIV testing uptake measured using self-report questionnaires and WCDOH health records
- 8. PrEP uptake measured using self-report questionnaires
- 9. Condom use measured using self-report questionnaires
- 10. PMTCT measured using WCDOH health records

11. QOL measured using self-report questionnaires I do not see that we asked this in the questionnaire

- 12. Substance use measured using self-report questionnaires
- 13. Alcohol use measured using self-report questionnaires
- 14. Mental Health Depression measured using self-report questionnaires and Center for Epidemiologic Studies Depression Scale (CES-D)
- Epidemiologic Studies Depression Scale (CES-D)
- 15. Education level measured using self-report questionnaires
- 16. Employment history measured using self-report questionnaires
- 17. Volunteerism, work experience measured using self-report questionnaires
- 18. Linkage to care measured using self-report questionnaires and WCDOH health records
- 19. ART uptake measured using self-report questionnaires and WCDOH health records
- 20. Viral load suppression measured using self-report questionnaires and WCDOH health records
- 21. Partner number measured using self-report questionnaires
- 22. Partner status measured using self-report questionnaires
- 23. Partner age measured using self-report questionnaires
- 24. GBV measured using self-report questionnaires
- 25. Transactional sexual activities measured using self-report questionnaires
- 26. Condomless sex measured using self-report questionnaires
- 27. Impact of cash on livelihoods measured using self-report questionnaires and in-depth qualitative interviews

Overall study start date 04/04/2017

Completion date 30/12/2020

Eligibility

Key inclusion criteria Both HIV-infected and un-infected young women aged 19-24 years

Participant type(s) Mixed

Age group Other

Sex Female

Target number of participants 10,000 young women: approx. 2500 women for care alone; approx. 7500 women for incentive + care

Total final enrolment 11494

Key exclusion criteria Does not meet inclusion criteria

Date of first enrolment 01/05/2017

Date of final enrolment 31/03/2019

Locations

Countries of recruitment South Africa

Study participating centre Desmond Tutu HIV Foundation Klipfontein/ Mitchell's Plain Health Sub-district facilities Cape Town South Africa 7750

Sponsor information

Organisation

Desmond Tutu HIV Foundation

Sponsor details

Faculty of Health Sciences University of Cape Town Anzio Road, Observatory 7705 Cape Town South Africa 7705 +27(0)21 4066959 Tammy.Buhler@hiv-research.org.za

Sponsor type Charity

Website http://desmondtutuhivfoundation.org.za/

ROR https://ror.org/02asra118

Funder(s)

Funder type Charity

Funder Name

The Global Fund for AIDS, Tuberculosis, and Malaria

Funder Name Health Department, Provincial government of the Western Cape (PAWC)

Results and Publications

Publication and dissemination plan Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

31/12/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	14/06/2022	18/01/2023	Yes	No